Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBRUTINIB vs BRUKINSA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy,Waldenström's macroglobulinemia (WM) in adult patients,Relapsed or refractory marginal zone lymphoma (MZL) in adult patients who have received at least one prior anti-CD20-based regimen,Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
320 mg orally once daily or 160 mg orally twice daily.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
4 hours (terminal), supports twice-daily dosing
Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism by CYP2D6. The active metabolite is PCI-45227.
Zanubrutinib is primarily metabolized by cytochrome P450 3A4 (CYP3A4). Following oral administration, it undergoes oxidation and further phase II metabolism. The major circulating metabolite is a product of CYP3A4-mediated oxidation.
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Biliary/fecal (87% as unchanged drug), renal (8% as unchanged drug)
97.3% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
96% bound to plasma proteins (mainly albumin)
Apparent Vd is approximately 10,000 L (large), indicating extensive tissue distribution.
3.23 L/kg (central Vd), indicating extensive tissue distribution
Oral bioavailability is 62% (range 52-74%) under fasted conditions; food increases AUC by 1.7-fold.
Oral: 48% under fasting conditions; high-fat meal decreases AUC by 30%
No dose adjustment required for creatinine clearance ≥25 m L/min. Insufficient data for patients with Cr Cl <25 m L/min or on dialysis.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 80 mg twice daily.
Child-Pugh class A: No adjustment. Child-Pugh class B: Reduce dose to 280 mg once daily. Child-Pugh class C: Reduce dose to 140 mg once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 80 mg twice daily. Child-Pugh C: not recommended.
Adolescents (≥12 years): 420 mg once daily; weight-based dosing not established. For pediatric patients <12 years: not approved.
Safety and efficacy not established; no approved dosing.
No specific dose adjustment; monitor for cardiac adverse events (atrial fibrillation, hypertension) and bleeding risk due to higher incidence in elderly.
No specific dose adjustment; monitor for increased toxicity due to age-related renal/hepatic decline.
Hemorrhage: Fatal bleeding events have occurred in patients receiving ibrutinib. Major hemorrhage (e.g., gastrointestinal, intracranial) has been reported. Monitor for signs of bleeding. Consider benefit-risk of holding ibrutinib for 3-7 days pre- and post-surgery depending on procedure.
None
Hemorrhage: Increased risk of bleeding, especially in patients on anticoagulants or antiplatelet agents. Avoid concomitant use of warfarin.,Infections: Fatal and serious infections (including bacterial, viral, fungal) have occurred. Consider prophylaxis in patients at increased risk.,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia have occurred. Monitor blood counts monthly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor cardiac function, especially in patients with cardiac risk factors.,Hypertension: New-onset or worsening hypertension has been reported. Monitor blood pressure and manage appropriately.,Second primary malignancies: Other malignancies (including skin cancers) have occurred. Perform skin cancer monitoring.,Tumor lysis syndrome: Risk is increased in patients with high tumor burden. Monitor and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have been observed. Monitor hepatic function.
Hemorrhage: Serious and fatal hemorrhagic events may occur. Monitor for signs of bleeding. Consider benefit-risk in patients requiring antiplatelet or anticoagulant therapy.,Infections: Fatal and serious infections (including pneumonia, sepsis) have occurred. Monitor for signs of infection and manage promptly.,Cytopenias: Neutropenia, thrombocytopenia, and anemia may occur. Monitor blood counts regularly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for symptoms of arrhythmia and manage appropriately.,Second primary malignancies: Including non-melanoma skin cancer, have been reported. Advise patients to use sun protection.,Tumor lysis syndrome: Can occur. Assess risk and monitor patients appropriately.
Concomitant use with warfarin or other vitamin K antagonists (increased bleeding risk) is not recommended but not absolutely contraindicated; use with caution.,Severe hepatic impairment (Child-Pugh class C) – use not recommended.
None
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they can increase drug levels and toxicity. Take with a full glass of water; may be taken with or without food but avoid high-fat meals as they may increase absorption variability.
Avoid grapefruit products and Seville oranges. No significant food effect on absorption; may be taken with or without food.
Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotoxic at exposures below the human AUC at the clinical dose. There are no adequate and well-controlled studies in pregnant women. Use during first trimester may cause structural abnormalities; second and third trimester use may impair fetal B-cell development and hematopoiesis.
Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of zanubrutinib to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity including increased post-implantation loss, reduced fetal body weights, and increased incidence of skeletal variations at exposures less than or equal to human clinical exposure at the recommended dose of 320 mg daily. Therefore, avoid use during pregnancy unless the potential benefit to the mother outweighs the potential risk to the fetus. If used, advise pregnant women of the potential risk to the fetus.
No data on presence in human milk, effects on breastfed infant, or milk production. Ibrutinib and its active metabolite are detected in rat milk at concentrations higher than maternal plasma. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after last dose.
There are no data on the presence of zanubrutinib in human milk, effects on the breastfed child, or effects on milk production. Zanubrutinib and its metabolites are excreted in the milk of lactating rats with concentrations approximately 2 times higher than maternal plasma (M/P ratio approximately 2). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with BRUKINSA and for at least 2 weeks after the last dose.
No specific dosing adjustments for pregnancy have been established due to lack of human pharmacokinetic data. Pregnancy may alter drug clearance via increased hepatic metabolism and renal function; however, no dose adjustment recommendations can be made. Use only if maternal benefit outweighs fetal risk, with consideration of therapeutic drug monitoring if available.
No specific dose adjustments are recommended for BRUKINSA during pregnancy due to lack of pharmacokinetic data in pregnant women. However, pregnancy-induced physiological changes (e.g., increased plasma volume, altered hepatic metabolism) may affect drug concentrations. Standard dosing (320 mg once daily or 160 mg twice daily) is used if treatment is deemed necessary, with close monitoring for efficacy and toxicity. There are no pregnancy-specific pharmacokinetic studies to guide dose modification.
Monitor for atrial fibrillation (occurrence ~6-16%, higher risk in elderly). Obtain baseline ECG and monitor for bleeding due to antiplatelet effect (avoid concurrent anticoagulants unless necessary). Check for tumor lysis syndrome risk, especially in high tumor burden. Ibrutinib is a strong CYP3A4 inhibitor; avoid co-administration with sensitive CYP3A4 substrates or adjust doses. Monitor for hypertension and myelosuppression.
Monitor for atrial fibrillation/flutter and hemorrhage; baseline ECG recommended. Dose adjust for severe hepatic impairment (Child-Pugh C). Avoid strong or moderate CYP3A inhibitors/inducers; use with caution in patients requiring antiplatelet or anticoagulant therapy.
Take exactly as prescribed; do not miss doses or stop without consulting your doctor.,Take capsules whole with water at the same time each day; do not open or chew.,Avoid grapefruit, Seville oranges, and starfruit during treatment.,Report any unusual bleeding, bruising, or black/tarry stools immediately.,Contact your healthcare provider if you experience irregular heartbeat, chest pain, or dizziness.,Use effective contraception during treatment and for 1 month after last dose.,Do not take with strong CYP3A4 inhibitors unless directed; avoid St. John's wort.
Take BRUKINSA with or without food, but avoid grapefruit and Seville oranges.,Swallow capsules whole; do not crush or chew.,Inform your doctor of any bleeding or bruising, irregular heartbeat, or signs of infection.,Do not use antacids, proton pump inhibitors, or histamine-2 blockers without consulting your doctor.,If you miss a dose, take it as soon as remembered unless it is less than 12 hours until the next dose; then skip the missed dose.
"Ibrutinib, a potent Bruton's tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. Saquinavir, a protease inhibitor and potent CYP3A4 inhibitor, may significantly increase the plasma concentration of ibrutinib by reducing its clearance. This elevation in ibrutinib exposure can potentiate its adverse effects, including myelosuppression, atrial fibrillation, hemorrhage, and infections, necessitating dose adjustment or alternative therapy."
"Ibrutinib, a Bruton's tyrosine kinase inhibitor, can inhibit organic anion transporters (OATs), leading to decreased renal clearance of sulfamethoxazole. This results in increased plasma concentrations of sulfamethoxazole, potentially enhancing its therapeutic effects and risk of dose-dependent toxicities such as hypersensitivity reactions, hematologic abnormalities, and crystalluria. Patients may experience prolonged QT interval or decreased renal function due to sulfamethoxazole accumulation."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBRUTINIB vs BRUKINSA, answered by our medical review team.
IBRUTINIB is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.. BRUKINSA is a Antineoplastic BTK Inhibitor that works by Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with the cysteine residue at position 481 in the BTK active site, leading to sustained inhibition of BTK activity. This blocks B-cell receptor (BCR) signaling, thereby inhibiting the proliferation, migration, and survival of malignant B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBRUTINIB and BRUKINSA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBRUTINIB is: Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.. The standard adult dose of BRUKINSA is: 320 mg orally once daily or 160 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBRUTINIB and BRUKINSA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBRUTINIB is classified as Category D/X. Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotox. BRUKINSA is classified as Category C. Based on animal studies and mechanism of action (BTK inhibitor), BRUKINSA (zanubrutinib) can cause fetal harm when administered to a pregnant woman. There are no adequate and well-. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.